Roche's gene therapy biotech Spark is laying off employees, ending some...
Roche’s Spark Therapeutics is letting staffers go and has “discontinued” several early-stage programs, a spokesperson confirmed to Endpoints News. “In May, Spark informed employees in an all-employee...
View ArticleClik here to view.
Mikael Dolsten isn’t the only one moving on from Pfizer; Lilly names interim...
Mikael Dolsten → As we learned on Tuesday, Mikael Dolsten is set to leave — but another Pfizer leader is already gone: Eli Lilly’s radiopharma partner Aktis Oncology has welcomed Akos Czibere as CMO....
View ArticleImmutep’s LAG-3 drug scores in Phase 2b head and neck cancer test
Immutep’s protein-based cancer treatment has succeeded in a mid-stage study in patients with head and neck squamous cell carcinoma, spurring discussions with regulators on a path forward. The Phase 2b...
View ArticleClik here to view.
Four key takeaways for biopharma from Labour’s win in the UK election
The UK’s center-left Labour Party won a landslide victory at last week’s general election, ending the center-right Conservative government’s 14 years in office. With new faces at the helm, UK biotech...
View ArticleIdeaya raises $302M; AbbVie to seek approval in giant cell arteritis
Ideaya closes $302.4M raise: The cash came in higher than expected after Ideaya said earlier this week it planned for a $263 million offering. On Monday, Ideaya presented Phase 2 data for a drug...
View ArticleMetagenomi science chief departs, just a few months after IPO
The chief scientific officer at gene editing company Metagenomi is out, the company confirmed to Endpoints News. “As of yesterday, I have parted ways with Metagenomi by mutual agreement,” CSO Luis...
View ArticleHow SCOTUS' decision in Chevron could change the way the FDA regulates biopharma
The Supreme Court’s decision late last month to overrule a decades-old legal doctrine will have major ramifications for the FDA and the biopharma industry it regulates. Legal scholars warn that the...
View ArticleTwo healthcare SPACs go public, with several more on the hunt for deals
The blank-check acquisition companies Launch One Acquisition and SIM Acquisition went public this week, a signal that the healthcare SPAC trend might not be totally dead. On Friday, Launch One began...
View ArticleClik here to view.
Indivior axes schizophrenia drug and shrinks revenue guidance
Indivior’s shares $INDV have lost nearly a third of their value this week, following the company’s announcement Tuesday that it was shelving a schizophrenia drug and had revised down its 2024 revenue...
View ArticleLilly says lupus drug dropped from pipeline failed to show efficacy
An experimental BTLA agonist that Eli Lilly cut from its pipeline for lupus late last year failed to show strong enough efficacy in a mid-stage trial, the company confirmed to Endpoints News. The...
View ArticleDeep dive on pay packages; Lilly strikes $3.2B buyout; Pfizer’s R&D head to...
Welcome back to Endpoints Weekly, your review of the week’s top biopharma headlines. Want this in your inbox every Saturday morning? Current Endpoints readers can visit their reader profile to add...
View ArticleClik here to view.
Roche details early obesity data from GLP-1/GIP agonist, plans for Phase 2...
Roche shared additional Phase 1b data for the obesity drug it acquired in the Carmot Therapeutics deal that suggest a higher dose had yet to peak at six months. An abstract, which is set to be...
View ArticleClik here to view.
Exclusive: Kins raises $7M to expand in-home and virtual physical therapy
(This story is from our new Health Tech newsletter. If you’d like to sign up, just click here.) As purely virtual care models become more popular, physical therapy startup Kins wants to give patients...
View ArticleClik here to view.
CordenPharma injects €900M to boost GLP-1 manufacturing in US and Europe
In its biggest investment so far, CordenPharma is earmarking €900 million ($982 million) over the next three years to expand its peptide platform capacity in the US and Europe to meet rising GLP-1...
View ArticleClik here to view.
Alzheimer's biotech Asceneuron raises $100M to see if it can compete with...
A small Swiss biotech has raised a $100 million Series C to start testing its oral small molecule for Alzheimer’s disease in a Phase 2 later this year. Asceneuron, a Merck KGaA spinout, is developing...
View ArticleVertex takes federal government to court over Casgevy fertility treatment...
Vertex sued the federal government on Monday in an effort to expand its fertility support program to certain patients taking its new gene therapy for sickle cell disease and transfusion-dependent beta...
View ArticleCatalYm raises $150M in Series D to repurpose obesity target for cancer
CatalYm has racked up $150 million in an oversubscribed Series D to advance its antibody drug that neutralizes GDF15 — a target previously explored by other drugmakers for weight loss — through Phase...
View ArticleAfter last year's ImmunoGen pact, Vertex finds another conditioning agent...
Vertex is partnering with a US and South Korean biotech to see if it can offer patients a better conditioning agent to make way for an infusion of Casgevy, the biotech’s recently approved sickle cell...
View ArticleBain-backed Cardurion raises $260M to fund ex-Imara drug, buy more cardio assets
Cardurion Pharmaceuticals is going shopping for more cardio drug candidates. The Burlington, MA-based biotech, which launched in 2017 with a Takeda partnership, has raised a $260 million Series B round...
View ArticleClik here to view.
Sionna licenses clinical-stage cystic fibrosis assets from AbbVie shortly...
Sionna Therapeutics snagged the exclusive worldwide license to three of AbbVie’s cystic fibrosis drug candidates as the biotech aims to beef up its work in the genetic condition and fill gaps not...
View Article